<SEC-DOCUMENT>0001640334-24-000137.txt : 20240124
<SEC-HEADER>0001640334-24-000137.hdr.sgml : 20240124
<ACCEPTANCE-DATETIME>20240124141207
ACCESSION NUMBER:		0001640334-24-000137
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240124
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240124
DATE AS OF CHANGE:		20240124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39874
		FILM NUMBER:		24555708

	BUSINESS ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrp_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:lxrp="http://lxrp.com/20240124"><head><title>lxrp_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-01-24to2024-01-24">0001348362</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-01-24to2024-01-24" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='lxrp-20240124.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2024-01-24to2024-01-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001348362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-24</xbrli:startDate><xbrli:endDate>2024-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2024-01-24to2024-01-24">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported) <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2024-01-24to2024-01-24" format="ixt:datemonthdayyearen">January 24, 2024</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:74%;vertical-align:top;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2024-01-24to2024-01-24">Lexaria Bioscience Corp.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td colspan="6" style="width:74%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2024-01-24to2024-01-24">000-52138</ix:nonNumeric>&#160;</strong></p></td><td colspan="6" style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;" colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2024-01-24to2024-01-24">20-2000871</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of incorporation)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Commission</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">File Number)</p></td><td colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="4" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Identification&#160;No.)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2024-01-24to2024-01-24">100 &#8211; 740 McCurdy Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2024-01-24to2024-01-24">Kelowna</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2024-01-24to2024-01-24">BC</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:countrynameen">Canada</ix:nonNumeric> </strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2024-01-24to2024-01-24">V1X 2P7</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td colspan="6" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number, including area code <strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2024-01-24to2024-01-24">250</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2024-01-24to2024-01-24">765-6424</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of each class</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Symbol(s)</strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of each exchange</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>on which registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2024-01-24to2024-01-24">Common Stock, par value $0.001 per share</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants to Purchase Common Stock</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2024-01-24to2024-01-24">LEXX</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">LEXXW</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The <ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The Nasdaq Capital Market</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Emerging growth company&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2024-01-24to2024-01-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Item 7.01</strong>&#160;<strong>Regulation FD Disclosure</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Christopher Bunka, the Chief Executive Officer of Lexaria Bioscience Corp. (&#8220;Lexaria&#8221;) has issued a letter discussing Lexaria&#8217;s strategic outlook and summarizing its accomplishments during the 2023 year.&#160; A copy of the letter is attached as Exhibit 99.1.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Item 9.01</strong>&#160;<strong>Financial Statements and Exhibits</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="lxrp_ex991.htm">99.1</a></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="lxrp_ex991.htm">Letter from the CEO</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160;</td><td colspan="2"><strong>LEXARIA BIOSCIENCE </strong><strong>CORP.</strong></td><td></td></tr><tr style="height:15px"><td style="width:50%;">&#160;</td><td style="width:3%;">&#160;</td><td style="width:35%;">&#160;</td><td style="width:12%;">&#160;</td></tr><tr style="height:15px"><td></td><td></td><td style="BORDER-BOTTOM: black 1px solid;"><em>/s/ Chris Bunka</em></td><td></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><strong>Chris Bunka</strong></td><td>&#160;</td></tr><tr style="height:15px"><td>&#160;</td><td>&#160;</td><td>CEO, Principal Executive Officer</td><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Date:&#160;January 24, 2024&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>lxrp_ex991.htm
<DESCRIPTION>LETTER FROM
<TEXT>
<html><head><title>lxrp_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEO LETTER TO STAKEHOLDERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">According to the Wall Street Journal, near the end of 2023, there were 446 companies listed on the Nasdaq that were trading under $1 and risking being de-listed; compared to nearly nil in 2021.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It was a tough year for microcap companies, which are often too early-stage to have profitable operations and withstand the harsh realities of the investment banking and finance industries: capital was <em>much</em> harder to come by in 2023 than at any time in recent years.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Considering the alternatives, we can at least breathe a sigh of relief and say, &#8220;we survived&#8221; and, in fact, made considerable advancements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While we made strong progress on the intellectual property front and signed a new corporate client from our newly created nutraceutical subsidiary, we faced real challenges in the capital markets that negatively affected shareholder value and overwhelmed our progress in other areas.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I always try to be as communicative as possible to all Lexaria stakeholders and so herein please find my thoughts related to our plans for 2024. <em>(All dates within this letter refer to calendar periods, not fiscal periods.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CAPITAL MARKETS and SHAREHOLDERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">XBI is the S&amp;P biotech index. It closed the final trading day of 2022 at 82.98; and the final trading day of 2023 at 89.29: a theoretical gain of 7.6%. I say &#8220;theoretical&#8221; because, if not for a rally during the last 3 weeks of the year in relatively few mid-cap biotech stocks, the index would have closed in a losing position. Combined with the regional banking crisis in the spring of 2023, that did not foster a positive environment for raising capital for nanocap companies. Thus, the devastation across nano-cap sectors as noted above by sub-$1 share prices.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria had to raise capital during 2023 to fund continuing operations and, thankfully, we were able to do so at a time when many small companies were not able to accomplish even that. But Lexaria shareholders paid the price with the worst development we have experienced at any time in the last several years: a horrific decline in stock price associated with raising capital. Lexaria management felt that was a manipulative, punitive experience that had us all feeling quite upset due to it being unrelated to other real-world and positive corporate events.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_ex991img9.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>LEXX stock price (daily bars) vs. XBI biotech Index (solid black line)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since then and on the positive side of things - because of our fantastic shareholders - the stock has climbed well above the $1 minimum bid price as required by Nasdaq to maintain our listing. We raised additional capital the first week of October on much less punitive terms which may be taken as a sign of confidence. Also, despite what had appeared at one time to be the inevitability of having to effect a reverse stock split in order to maintain our Nasdaq listing, we escaped that outcome and at this time, have no plans nor appetite to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria welcomed a number of new shareholders this year who saw the value that presented itself after the May market shenanigans and have been accumulating LEXX stock ever since. If there is good news in all of this, here it is: we have never before had so many new shareholders who so thoroughly understand the Company and its objectives. THANK YOU for your support.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indeed, by the middle of October with the combined decline of the biotech index and the marginal advancement of LEXX; LEXX was once again in a position of parity. Really, it is only the final month of the year where the biotech index has shot back up and LEXX has not. Hopefully that situation will be remedied sooner rather than later.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As promised, we also did NOT take on any debt during 2023, and I have no intention of doing so during 2024. My rule of thumb remains valid until proven otherwise: until such time as we have back-to-back quarterly profitable operations, I do not want to burden Lexaria with debt.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">According to the Nasdaq, LEXX had a registered short position of 778,075 shares as of Dec 15, 2023, which was more than double the average level during 2023. Of course, it is not possible to know the unregistered naked short position although I presume it is much higher than that. Why Lexaria remains of such interest to short sellers is a mystery, but one that will have a happy ending (for <em>us</em>, not for them) if we manage to achieve our objective of executing a major collaboration with a large corporate partner.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 19, 2024, we filed a Form S-8 Registration Statement with a reoffer prospectus (the &#8220;S8&#8221;), in order to effectively register the additional shares issuable under our Incentive Equity Plan (the &#8220;Plan&#8221;) as approved by our shareholders on May 9, 2023 and to allow our insiders the ability to trade any shares currently issuable to them under the Plan. The filing of an S8 does not mean that insider selling is imminent! In fact, Lexaria has had a valid S8 in place since our listing on the Nasdaq and to date no insider has sold any shares pursuant to it. Every situation is unique, but as a rule, paying much heed to the &#8220;short and distort&#8221; community is not a smart way to manage your investments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I wrote extensively last year about the strategic wisdom of pursuing licensing and Research and Development (&#8220;R&amp;D&#8221;) collaboration deals, and I encourage you to review last year&#8217;s letter to refresh your memory. Despite our best efforts we only managed to close one new corporate customer during 2023. Generally speaking, it is hard to convince companies active in the consumer-packaged goods (&#8220;CPG&#8221;) sectors to pay for technology to improve their product offerings. Profit margins in those sectors are thin, and we&#8217;ve learned that most companies operating there simply do not have the ability to pay for technology. In light of this, we are concentrating our focus on our rapidly growing biotech and pharmaceutical objectives where technology partnering ability and interest is much higher and commonly practiced.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Last year we provided a table of our ten largest institutional shareholders who collectively owned 690,344 shares according to their then current disclosures.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This year, either <em>one</em> of our top two institutional shareholders own more stock than ALL the institutions combined did last year. Although the data is quite old (it is the most recent available), it is still heartening to observe that more and more institutions (19 holding an aggregate 1,805,504 shares) are taking an interest in us &#8211; see our table of the ten largest institutional shareholders below. We extend our thanks in particular to Invenomic Capital Management who have been shareholders for a long time and who have accumulated more stock throughout the year &#8211; we appreciate your support.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Owner Name</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:33%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:33%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Held</strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Armistice Capital, Llc</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">889,272</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Invenomic Capital Management Lp</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">764,332</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Boothbay Fund Management, Llc</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">78,950</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geode Capital Management, Llc</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">47,416</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Vanguard Group Inc</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">33,329</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Renaissance Technologies Llc</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,900</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Two Sigma Securities, Llc</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,545</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Tower Research Capital Llc (Trc)</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8,330</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1832 Asset Management L.P.</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,686</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Wells Fargo &amp; Company/Mn</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,086</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FOOD AND DRUG ADMINISTRATION (FDA) REGISTRATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We had expected to file our Investigational New Drug (&#8220;IND&#8221;) application around the end of August in 2023, but as you know that was delayed because of overdue delivery of required analytical and stability information from one of our core ingredient suppliers. That put us in a tough position where we could either abandon that supplier and all the work including GMP production work that we had completed using their material (which would have been a delay likely of 9-15 months and a cost of at least $600,000) or try to work with them to remedy the situation. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I apologize for the roughly 5-month delay, but there truly were no great choices for us to pursue. However, the supplier has now received most of the information from their contracted laboratories to satisfy their paperwork needs which will enable us to soon submit our application to the FDA. Stay tuned for updates on our IND filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>RESEARCH &amp; DEVELOPMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria remains committed to achieving success through innovation. It is not necessarily an easy path and, while setbacks must be expected, we have been very fortunate that DehydraTECH continues to impress. Lexaria has enjoyed a high rate of success in its R&amp;D pursuits for many years, and 2023 did not disappoint. Although no technology and no company is capable of producing a 100% rate of success in R&amp;D programs, we have truly been blessed with positivity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because we focus on innovation, later in the year we took some chances and experimented to learn whether DehydraTECH might work with an entirely new class of molecules that we had never worked with before. That educated risk-taking may have led to the most important discovery in the Company&#8217;s existence. Read on!</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Hypertension. </strong>In February 2023 we issued follow-up results from our 66-person DehydraTECH-CBD hypertension study HYPER-H21-4, wherein we communicated our discovery that we had lowered the quantity of catestatin in the human blood stream. This could have important implications for better understanding a mechanism of action of how cannabidiol processed with DehydraTECH was capable of lowering human blood pressure, and further implications with a potentially positive bias towards our regulatory pathway for same.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In May, we released our final set of results from the DehydraTECH-CBD hypertension study HYPER-H21-4 wherein we reported on DehydraTECH-CBD&#8217;s ability to lower <strong>interleukin inflammatory biomarkers</strong> by statistically significant amounts of between 19% and 43%. At the time, Dr. Phillip Ainslie, Scientific Advisor to Lexaria in the field of cardiovascular diseases and Lead Investigator to our hypertension studies, remarked that, "<em>There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen. The bigger picture is that inflammation is the key basis of atherosclerosis, and several pro-inflammatory agents have been examined as potential mediators of the biochemical pathways of lesion formation. Other &#8216;common' diseases or disorders associated with chronic inflammation include fatty liver disease; Type 1 &amp; 2 diabetes mellitus; inflammatory bowel disease; asthma; lung diseases chronic kidney disease; rheumatoid arthritis and obesity. Part of the reason why many of these diseases lead to cardiovascular disease is via chronic inflammation."</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cholesterol, Triglyceride and Weight Loss Management. </strong>In March 2023 we released news detailing the results from an 8-week study in 32 rodents wherein a new, unique version of DehydraTECH-CBD had impressive results related to diabetes and weight loss. In that study &#8211; planned and executed mostly before the world was deluged with information regarding weight loss from the GLP-1 drug classes &#8211; we demonstrated that this specific version of DehydraTECH-CBD lowered triglyceride levels, and surprisingly, body weight differential during the 8-week study period. Lexaria shareholders know that we are a data-driven company: instead of following narrow &#8220;top-down&#8221; mandates, we follow the data. In this case, the discovery that DehydraTECH processing of cannabidiol enabled previously-unknown benefits of great interest to diabetics caused well-founded excitement within the Lexaria management and scientific teams. This was the birth of our interest in the fields of diabetes and weight loss and sparked our subsequent work in the GLP-1 sector, noted below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Human Hormones. </strong>In May 2023 we informed the world that DehydraTECH processing of the human estrogen hormones estradiol and estrone greatly enhanced their ability to be absorbed into the bloodstream in a study of 20 rodents. Delivery improvements of 900% through to 12,500% were achieved; highlighting the dramatic improvements that DehydraTECH processing can offer to the normally poor bioavailability of orally-delivered hormones. Although these early-stage results were compelling, we lacked the budgets to conduct follow-on studies.&nbsp; However,&nbsp; when budgetary constraints lessen we hope to pursue additional studies to further validate these exceptional results. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Blood Glucose and Diabetes. </strong>We had continued to process the data from our March 2024 animal diabetes study, and in June we were delighted to be able to report that our uniquely formulated DehydraTECH-CBD was also able to reduce blood sugar by a statistically significant level of 19.9%. According to the Center for Disease Control,&nbsp;managing your blood sugar levels&nbsp;is important to avoid diabetes-related conditions such as vision loss, heart disease, and kidney disease.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As if that was not enough, we also examined kidney function in the animals and discovered that we had reduced the ratio of blood urea nitrogen to creatinine by a statistically significant 55.1%. This is yet another area of investigation where we will have to conduct additional research at some later date, give the significance this discovery could have to those suffering from kidney diseases.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Reduced Risk Oral Nicotine. </strong>Last summer we reported results from our long-anticipated human oral nicotine study. That study demonstrated that when Lexaria&#8217;s technology is applied to oral nicotine, the speed of absorption into the bloodstream is faster than the #1 brand of oral nicotine in the world, Zyn&#174;, and also faster than the #3 brand in the USA, On!&#174;. That study also carefully evaluated subjective performance, and the study participants rated DehydraTECH-nicotine as #1 for experiences such as euphoria, tolerability, pleasure; with DehydraTECH-nicotine generating the <em>lowest</em> incidences of mouth and throat burn, nausea, and hiccups; compared to Zyn and On!.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Glucagon-like Peptides (GLP-1)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the summer of 2023, Lexaria quietly launched our own top-priority and unpublicized early-stage work program into the drug categories known as GLP-1 for weight loss and diabetes control. This was a high-risk program, not least because this class of drugs are known as &#8220;large molecules&#8221; whereas all of Lexaria&#8217;s previous investigations had concentrated on &#8220;small molecules&#8221;.&nbsp; As we didn&#8217;t know whether DehydraTECH would have any positive effect on large molecule drugs, we wanted to avoid implying publicly that it might work before we had evidence either way. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At the end of November and again in early January, 2024, we were delighted to report positive interim and final human pilot study results respectively, using a DehydraTECH formulation prepared using crushed Rybelsus&#174; semaglutide tablets.&nbsp; This investigator-initiated study represented our foray into the GLP-1 space, performed by a university research center. Frankly, the results surprised us with their level of positivity.&nbsp; It was found that DehydraTECH processing:&nbsp; delivered a statistically-significant higher proportion of the semaglutide, and did so more quickly (very typical results for our technology); reduced the quantity and severity of unwanted side effects; and had a statistically-significant impact on blood sugar in general and much more effectively after eating a meal, than did Rybelsus. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Blood Semaglutide Levels (mmol/L)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_ex991img10.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rybelsus Control (<font style="color:#4f81bd">blue</font>) 7mg (n=7)&nbsp;&nbsp;&nbsp; DehydraTECH (<font style="color:#c0504d">orange</font>) GLP-1 7mg (n=7)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To be clear: these were the results of a very small pilot study of only 7 people and there are risks in drawing too strong a conclusion from such a small group of healthy volunteers. The main purpose of the study was to provide direction as to whether or not DehydraTECH would even work in the large molecule GLP-1 sector, and it more than met that objective with the noteworthy achievement of statistically significant results. As before, we are &#8220;following the data&#8221;, and DehydraTECH GLP-1 investigation will be an area of primary focus for our R&amp;D investigation during 2024, given the positive momentum and need in that market sector. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Blood Glucose Levels (mmol/L)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_ex991img11.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Rybelsus Control&nbsp; (<font style="color:#4f81bd">blue</font>) 7mg (n=7)&nbsp;&nbsp;&nbsp; DehydraTECH (<font style="color:#c0504d">orange</font>) GLP-1 7mg (n=7)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>About GLP-1 Drugs</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Rybelsus (semaglutide) is the only GLP-1 drug approved by the FDA <em>for oral dosing</em> to treat diabetes and weight loss. The FDA has also approved semaglutide marketed as Ozempic&#174; and Wegovy&#174;, <em>administered by injection</em>, to treat diabetes and weight loss. All three of these drugs are owned and manufactured by Novo Nordisk&#174;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">GLP-1 drugs have recently been approved by the FDA for type two diabetes and weight loss management. Weight loss of between 10 pounds to 33 pounds, or more, has been widely reported. One 68-week study of 667 people reported an average loss of 15% of body weight.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Anecdotal commentary also suggests that some patients are experiencing reduced cravings for alcohol, nicotine and opioids while taking GLP-1 drugs. Other trials are examining their effects on heart disease and even dementia in part because of evidence that GLP-1 drugs may reduce the build-up of the proteins amyloid and tau in the brain, thought to be partly responsible for Alzheimer&#8217;s disease.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Side effects of GLP-1 drugs vary but can include nausea, vomiting, diarrhea and more. A small number of GLP-1 drugs have already been tested or approved in oral format but some studies have reported worse side effects with the oral form. The drugs are also being investigated for their relationship to bone density, muscle loss and more. Because of potential serious side effects, it may be beneficial to treat patients with lower oral doses of the drugs, something that Lexaria&#8217;s DehydraTECH technology may enable if it can improve the PK performance of GLP-1 drugs through oral capsules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because GLP-1 drugs have experienced FDA approvals as recently as 2021 and 2022, and because the health benefits of this drug class are still being discovered and understood, the potential market size is unknown. Published reports are widely estimating $100 billion in sales per year, by 2030. At least one analyst from Guggenheim Partners published a note on September 12, 2023 in which he explained how &#8220;the total addressable market for these so-called incretin drugs could balloon to $150 billion to $200 billion.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We had a successful, active year of R&amp;D. For some shareholders that has been overshadowed by the dismal performance of our stock &#8211; and I can assure you that no one is more frustrated by that occurrence than I am. Our talented team remains focused on what we do best and we believe that our hard work, innovation, vision, and determination to continue in the face of challenges will culminate in success. Lexaria has beaten the odds so many times that I have lost count. We&#8217;ve been poked at by some who are not eager for us to succeed. But we will continue to focus on the hard work of producing hard, factual scientific information that, sooner or later, will prove its worth.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">And, though I&#8217;ve been wrong before, I think 2024 will be that year.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024 R&amp;D Plans</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our R&amp;D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations. This annual letter is meant to be a guide, and we reserve the right to &#8220;change course&#8221; in our plans that are current as of the day I write them &#8211; but they might change, and they might change significantly based on any number of factors including our need to raise additional capital. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For 2024, the GLP-1 drug category will be our primary area of focus. The good early-stage results achieved in 2023 need to be followed up thoroughly and we expect to perform some or all of these studies in 2024: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Human pilot study #2</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Human pilot study #3</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Multi-arm, 12-week animal chronic study</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Human chronic weight-loss and diabetes study</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Multi-month stability testing of DehydraTECH GLP-1</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will generate a lot of data from all these GLP-1 studies. Our intention is to demonstrate the superior pharmacokinetics and safety/efficacy performance of GLP-1 drugs when formulated and processed with DehydraTECH, to such a degree that we attract a large pharmaceutical partner. Our historical work with other classes of molecules is helpful to guide us along this new path with more knowledge and rapidity than we were ever capable of in the past.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the hypertension category we expect to focus on trying to achieve FDA approval asap for our Phase I(b) DehydraTECH-CBD study. Doing so would represent the culmination of nearly 18 months of work and give us the regulatory clearance to begin this all-important registrational human study designed to evidence safety, tolerability, and efficacy of DehydraTECH-CBD in reducing blood pressure. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A lot has happened in the last ~18 months since we started working on the IND project, including a big downturn in the small-cap biotech sector. As a result, our valuation today is less than it was when we started the IND process. We want to balance our desire to initiate and complete the hypertension study as soon as possible, with our shareholders&#8217; desire to not dilute the Company more than necessary, especially while we are in this temporary situation of depressed stock prices and valuations sector wide. As a result, we plan to wait for stronger market conditions and a hoped-for improvement in our valuation before we finance the hypertension study so as to minimize dilution for you, our shareholders. Thus, we do not know at this moment when we will begin the study following expected FDA &#8220;approval&#8221;, as this largely depends on market conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">That said, we DID make real progress during 2023 including performing certain pre-study preparatory tasks in order to proceed as quickly as possible with study initiation, when funds permit.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Given the overwhelming interest in the GLP-1 sector, we are not at this time planning additional 2024 research in the antiviral, nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time. That is a gentle reminder to all that our data does not have any practical &#8220;shelf life,&#8221; per se. When we conduct early-stage R&amp;D it often serves a primary purpose of allowing us to more confidently apply for patent protection using the study-dependant data. Those patents, when granted, can form the foundation upon which future commercial relationships are built. And so, even if we do not immediately follow up with more advanced or broader R&amp;D in a particular category, the advancement of our ever widening intellectual property portfolio continues. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COMMERCIAL RESULTS AND COLLABORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We had great hopes last year that the new customers signed during 2022 would have a significant impact on our revenues during 2023 and beyond. Chief among these was Premier Wellness Science Co., Ltd. (&#8220;Premier&#8221;) of Japan &#8211; our first client in Asia. Premier was a subsidiary of a Tokyo Stock Exchange-listed company, Premier Anti-Aging Co., Ltd. and this year was amalgamated into the parent company.&nbsp; Premier failed to launch any products under our agreement together during 2023 and we are unsure of their direction going forward. As well, our other licensees who are focused on non-pharmaceutical CBD have not made the progress we had expected. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have pursued opportunities within the CPG sectors for a long time and have learned that, in part because profit margins are generally so tight in most ultra-competitive CPG sectors, convincing these companies to pay to use an enabling technology like DehydraTECH is no easy task. Many of the young companies fail to get traction whereas most of the established companies are resistant to any change. While we expect to remain opportunistic within the CPG sector we will do so without overly devoting resources to this sector where positivity is elusive. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Instead, as we expect our IND to be filed and as we also pursue R&amp;D outcomes in the GLP-1 sector, our corporate focus is continuing the transition towards the biotech and pharmaceutical sectors which we embarked upon some years ago. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The pharmaceutical industry values drug delivery technology more wholesomely than does the CPG industry. This is apparent in the 2020/21 transaction whereby Novo Nordisk paid US$1.8 billion to acquire Emisphere Technologies Inc. Emisphere&#174; developed a drug delivery technology now known as SNAC, &#8220;which facilitates the enhanced oral absorption of molecules without altering their chemical form, biological integrity or pharmacological properties,&#8221; which, as far as we have been able to determine, are properties also enjoyed using DehydraTECH. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">What makes this transaction of even more intriguing interest, is that this is the technology now in use in the Rybelsus&#174; tablet delivering Novo Nordisk&#8217;s blockbuster GLP-1 drug, semaglutide. And as showcased above, the Rybelsus&#174; tablet incorporating the SNAC technology is the exact material that Lexaria improved upon the delivery characteristics with DehydraTECH in our recent human pilot study.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria will continue pursuing all commercial opportunities wherever they may lie. But our focus has shifted to those markets that are willing to recognize the excellence that DehydraTECH delivers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>INTELLECTUAL PROPERTY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria received 10 new granted patents during 2023: more than in any previous year, with a total of 38 patents now granted worldwide. Our patent portfolio provides vital support to our commercialization efforts.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our international patent portfolios in the USA (3 new) and Canada (5 new) experienced notable growth. In the USA we received particularly important patent grants for treating hypertension<em> </em>and, in both the USA and in Canada, important patents were granted for sublingual delivery of nicotine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We currently have patents granted in the following countries:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:33%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Patent Families</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:33%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Patents Granted</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Australia</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Canada</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">European Union</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1*</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">India</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Japan</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mexico</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">USA</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">13</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 56.7pt; text-align:justify;">* validated in 10 EU countries</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We continue to expect additional patents to be awarded in the future although we have already achieved significant intellectual property protection through our existing patent portfolio. Regardless of the number of patents granted it is impossible to achieve &#8220;perfect&#8221; protection.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We also retain many valid patent applications throughout the world, some of which are likely to advance to granted patent status. Although we do not receive a granted patent for each application we submit, and while we expect the growth in our patent portfolio to slow, Lexaria&#8217;s intellectual property is as well protected as we have been able to achieve. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SUMMARY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2023 was an &#8220;interesting&#8221; year: we successfully completed a number of important research projects and we were awarded more new patents than during any other year in our history. We had no choice but to raise capital and were severely punished because of it. That said, we have since received roughly $800,000 from the exercise of warrants associated with that financing, and the additional working capital is welcome. Our revenue generation is a welcome additional to our income statement but remains mostly insignificant and irrelevant to our much more ambitious goals of seeing DehydraTECH actively in use by a &#8220;Fortune-500&#8221;-type company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Late in 2023 we discovered that, against all odds, DehydraTECH seems to have a dramatic and positive effect on the oral delivery of a GLP-1 drug known as semaglutide. That drug, owned by Novo Nordisk and sold under the brand names Ozempic&#174;, Rybelsus&#174;, and Wegovy&#174;, has propelled Novo Nordisk to become the most highly valued public company in all of Europe.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This was also our first-ever evidence that DehydraTECH could enhance delivery performance of so-called &#8220;large molecules&#8221;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I am more positive than ever before about our chances of establishing a commercial relationship with a significant pharmaceutical company in the year to come.&nbsp; Why?&nbsp; Because:&nbsp; we have never been more confident in our intellectual property portfolio; we have witnessed consistent drug delivery improvements with a variety of molecules; we have established a foundation for our studied molecules to better qualify them for commercial use and have learned what must be done in advance of gaining a corporate partnership; and we have now demonstrated DehydraTECH&#8217;s superiority with one of the most valuable molecule classes in the world (GLP-1). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our 2024 research program for GLP-1 drugs is ambitious but logical. It is well within our ability to execute (subject to some financing needs). And, if it continues to deliver results similar to those we&#8217;ve already seen, together with our ever-advancing progress on DehydraTECH-related intellectual property, I&#8217;m just not aware of what else we would need to do in order to find a </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">strong commercial partner.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have been a shareholder of Lexaria for a very long time: I know how our shareholders feel as you watch our progress because I feel most of the same things you do. I&#8217;ve always tried to be straight-up with you even as we&#8217;ve juggled some daunting challenges. We have new shareholders in 2023 who have enthusiastically supported our most recent corporate strategies &#8211; to you I offer a special &#8220;thank you&#8221; for your support and I pledge that I will do all that I can to turn 2024 into the year that Lexaria leaps forward. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Thank you for giving us this opportunity to work our way forward.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><img src="lxrp_ex991img12.jpg">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>About Lexaria Bioscience Corp.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp.&#8217;s patented drug delivery technology, DehydraTECH&#8482;, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, GLP-1 and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, please visit <u>www.lexariabioscience.com</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company&#8217;s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements.&nbsp; As such, you should not place undue reliance on these forward-looking statements.&nbsp; Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company&#8217;s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&amp;D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria&#8217;s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).&nbsp; Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>INVESTOR CONTACT:</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>George Jurcic - Head of Investor Relations</strong><strong> </strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><u>ir@lexariabioscience.com</u><u> </u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Phone: 250-765-6424, ext 202</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrp-20240124.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/24/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:lxrp="http://lxrp.com/20240124" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lxrp.com/20240124">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://lxrp.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20240124_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20240124_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20240124_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20240124_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
 <import namespace="http://fasb.org/srt-roles/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd" />
 <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
 <import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
 <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
 <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
 <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrp-20240124_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/24/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address Country</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>lxrp-20240124_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/24/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://lxrp.com/role/Cover" xlink:href="lxrp-20240124.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lxrp.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lxrp-20240124_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/24/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lxrp.com/role/Cover" xlink:href="lxrp-20240124.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lxrp.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lxrp-20240124_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/24/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://lxrp.com/role/Cover" xlink:href="lxrp-20240124.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lxrp.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lxrp_ex991img9.jpg
<TEXT>
begin 644 lxrp_ex991img9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $M G # 2(  A$! Q$!_\0
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M@U(VV$M";^,MNPN%SG Y+9//W:UKKQ-X?L=2;3+C4(UO4D@A:((S%'FR(E.
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M"'_CVD_PU['7G/@>S^(T&J7#>,[R&:R,"^2J^66#YXSL4?,!G<>A)&.]>C4
M>7>)+7P:?$-]-J?A:]N[J$><;R)'.]O+._:<@$JFT8&?O# X-5->O/!NK7=K
M9:EH>L27DMW^[A7>HMY2X4OPQ49;G<,YZ].:Z[6YO%EO=O\ V(UA,-T>([H[
M<!@0V<$$X*KCIG>?[M2^&[CQ'<"Z7Q!]D!41B+[*P8'CYB2#GD^PH R;?QA9
MZ;9-:KH=\(;5=J?9HVF7:&8;<X!W *21VZ9)(S6NO&FAZ_IUY8ZEX=U:2S;*
M3 P@(R[P 0P8$@G;R.,9.< FO2** /"O$&I^![6YT'P_JOA'4KNSUR/[<"]W
M(T4,LC.Q$GS??)W')ZD8Z@"NM^$-QX=N_!4EQX9T&30;1KV826<DC.0XP ^3
MV9!&P]FIWBB'XD?\)CI<WA6ZM?[!$86^@GVAV;+?,A()X&T$=\^HYU_ \?C"
M'PX8O'$T$^JK<2,)H2I#1,=R#Y5497.SISL!YSF@#KSTKR32-6TN*>VUBT\(
MRZ>L*Q6JS)<':%;D(0!\Q&>0,G).<=3ZT>AQUK@;B]^(DT/EV6E6,9^RHIFF
M=6?S\?,0 ^-O0C_Z_ !WJMN0-ZC-<7XBNM'A\1Z);WUG(6GO7'VX7!@6SE%K
M(5).03N3<G''//.*@N+KQ]'K4T-A;V5Q:M<+_P ?#*OD0[5R0%;<3G<<'TP#
MWIMU>_$:UCN)O[+TZ[52BQQQ EG)7EL;N &PN,]"6SQB@#/\(ZOI-YXLB@M?
M#,NFW9M;]M[7 D:+%\1*CJ"0N^3YU/3&0.!7I]9.COJTECNUJWA@N]Q!6'[N
MW)QW/:M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *R-4U#[#IYN/)$H+*GS-M1<G&YFP<+[X-:]9>J27\4<#:=#YS^<OF
MIE06C_BQN(&>E '"^!+CPWI*1>%=#T:ZTIY?-O3;SA1@LP<G.<D?.H&!P!C@
MJ17H%Y8VM_926=Y L]O*NUXW&0P]#7)Z6WC:?7;2XU;3]/M;<!UG:W(=V3YM
M@W%L@="<9Y]>W<&J*E*3ES-Z]SS77/#?AWP_X.O)+S^T[RTMW>\-N;N0M.^2
MY#$<D$@\MT_ 5P5UK'@9-$%C:^%[PVPM6UHQ1:DT?ESG"LBG.=V%^7U+@ 9:
MO>KC?-:S);W'E3%2J2 !MC$<'!X/8X->:WD?Q2GT^P6WNX[6ZMM.B6Z<R6[)
M>W2LF\C@&)<A@6&>&X4$#,C]I+N_O/4+4@JY&0"P(!Z_=%6:KV^[][N^]OYQ
MZ[15B@@**** .)\:+H?V6 :]-+!;*6=)(W*8<1R=2!P<;B/5@*RUA\/Z9/<0
MW&M:E(+P7.4DN)&6-0B%SRO&Q7&#_M'KCB;XD7%U'HD$=OKFGZ.TMQ$3+?P&
M57*,74* #SN4'D=*KW&I60\4"S6\T^;4C.JR9T\[V;<J;2X7J>!GH  : $31
M]'*7%Q#KFH1@31B1+<^2%D8# 50@"\8;';)/>F7H\.OHN@1-K[PW6D3?;[5I
M\O<,0K1_-&V"1^\_E5BQUJTFD>&:\T^>"V;?=16]C(C@ARB^7Q\P5\YP"<?7
M%5?MVGV^EQ7PDLFC%H1'.ECN%N.O $>1\T4IVX '>@"IH'A30M \2OXP777N
M7MH)&F$46(I!-*WS@(#C!!7"@ ;?J3WFH>(+/3;D6]X'5LH,HCNOS$@9(7 &
M1R3P*YW3K_0K![C3]=U#3)(IT6)(Y8"BS[<N0H88?[^<#/)]>O2VMOI=X&NH
M=/M6^;RV+P ,"CG@\=F!Q[\T <KXFBTN^NY[RXU"[LW@)#26ZLP_=89U!"Y
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M (4SS9_,V>2F<$_ZP_X5/^\]JB7S/M'\/W3_ #H 7=<9 \I.?^FA_P *"UP
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MQ9YM+MI&=M[%H5)9L;<GCKCCZ5:M[=+5?)MXUCCZ[1ZDDD_F:FC+[!\H_/\
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MRC\__K4 -_>?:6^[]P?S-.?S-O\ #U'\Z9E_M1^4?<'?W/M3G+[?NCJ._O\
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M]0:"N5\O-T-)V;Y?E/WAW%/^;^Z?TJ">800/,ZMLC!9L<G &:Y[1_%VCZ])
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MIJL=S?*W7V]* $9FW)\AZ^H]*29FPGR'[P[BE9CN3Y6Z^WI23,<)\C?>'I0
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M-/N+&\A%Q:W"/%-%(N5D1LAE([@@D4 8OA,M<V=]K!0B/5;R2[A]XL+'&W_
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M[2-5N[V[:/5&MK><1A3$T@DC"Y)(YP"3@>F!R">:+&:FX24DM4.\%Z/>>'_
M&@Z'J$QFO+*QB@F<MO&]4 (!P,J#P..@%;\S#RYN&^Y_=/O571[>YL=&MK6]
MN&NKA% >;!^<^M6IG'ES<-]S^Z?>F0-N#FW?[WW3_"?2N)\%^'='A^'UE'#I
MZ)]O@M[NXQNS+*$0AR?4;5_(5T.KW&KQW%O_ &;:/<*5D\Q2 %)"G8"201EL
M=,\9SVJ+P_-KTD,XURR2TVLHACA^8!=JYY'^UN_"D5&;C%I=TS'\%:+JEG-J
M>L:Q>27-U?[(ECD@".D<+R!"Q!PS%6!SA>W%4-6U#5M/^)%S9:'%;O>WMG;W
M++<*VPPQ"?>,KRI+>6H;!QNZ'I7HJL, _-C_ '36.NA67_":OXIRYO6L%T\*
M1\JQB0R9^I)'Y"K(E+FDY6M=EW2]0CU/1[#5(XV1;RW2=4(R5#*&Q^M8E]XH
M:Q\6>'=!AMUGAU2.Y:2<-_JC&H*8]=QW#\*Y^SGFF\$^&_#\,TL4]W,]E,T;
M%76W@9O-P1R,B,)D<C?QS66FBW/AYM5NGT_[-I6B7ED=+9!A3;&<R2J!V""9
MD^B"I$=]K&K6MC)#8W&T+<QR99I FT*N2<''';(Z$BN9CA77/#(ATO16M[S3
M)+>WBANI L@BCEBD*%AD#*H.YR1SBO1&6-C\T>XCN5S38_+4MMCV\]EQ2W'%
MRC;EZ.YS'@_34\/^%=.\,F^^V76FVZ1S-N9B"1GOR!UV@]  .U=.S (WWNA_
MA->?6^I7&G_$_489V@:VO6C7>24:(K%E1SPV>><CJ.*UYO%5M8>+=4TS5+JW
MM+.UL;>YA>3*L[-]H,GU 6$'@?WJ:9M5I2BU;6Z3,GQYXIAL+ZV\-S6MR?MR
M13F2*)Y 4%U#&\;!5. RN1R0#TYS6=\%Y"OA%K>98UG2*S9DA#%0ILX AR0,
MD@<^^>V*E:XT?Q-\5$MK>X>=+726,P"LC(Z7<,B9R!P2F1V(SCBNG\,Z;#HM
MUJEC#;_9+19XUM(N>8DMH4^7/) *D9]J74I-*FXM69U <;VX;M_":5G&5X;K
M_=-('&]N&[?PFAG&5^5NO]TTSF';Q_M?]\FFQN-@X;_ODUFPZMILWVGR;R)_
MLLWV:<[L".7"G8?0_.O'^T*TT<;!\K?]\F@"%YHXGDDD)5$CW,Q!P ,YK \'
MJW_"+P:A,I6?4Y'U"08/'FOO4?@I5?PJYXFN/(\+ZY. W[O3IFZ>B,:MZ9%]
MET*PM<-^Y@BC^Z>R@4 7]X_VO^^335<;>C=3_"?6G;Q_M?\ ?)IJ.-O1NI_A
M/K0 ;QYG1NG]TUYEXHT5_"_]L^-K8SW]TVI6UY':I$<H@00&-<<G<9'8G_:]
MJ]-WCS/NMT_NFAG^7@-^1H R="T_^Q]!MM-=C)+!;J)7 /[R0Y+M^+%C^-;&
M\8Z-_P!\FHBP\R;AON#L?>I=XQT;_ODT ,5QE^&Z_P!T^E#.-Z<-W_A-"N,O
M\K=?[I]*5G&]>&[_ ,)H YGQ)(MOJOAJ\;Y5BU+RF9N !)#*@R?=BH^N*YWP
M7J4.GR>(=2U6\6UMM3GAUA9+E]JHMP3%&N3P.(8P/<^]=SJEC8ZOIEQI>H6X
MN;2Z4Q2Q.IPZGJ/_ *_:N>O/!L-YXHTR\;9_8]I9FWDTYHMRSLI_<YSQM0/+
MP>I*GM0!UL+!+=-P887G*GBN1\!Z?9P^&K'5A:HNH7]JC37'E_/(I9Y$#'N
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MQFTM&*!NNTD XZ9 KU(R)O7YO6N!\#Z?8^&3=>&SK7]HWP<3R P&$QKY<<2
MC)'2(<YY))%=^SIO3YQ^=4<X-(FQOF[4HD38/F[4C.FQOG'3UI0Z;!\PZ>M
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MPVL*GRHXX_E/W0!_GJ:!W>W0F;;S\U<OXPL)K[PW=?8K);R^B=&A08#9W(2
MQ^[D#DUU>Y/[P_.HU:,M+\P^]Z^PI;A"3A)271W/&=<\ WWAVVO=6T?6KJY0
M&6\NA<2XG$A%PYDC<8"8:;A%4+@'N23!X;U"ZF^-CZ8N/L<=QJ-XW[M@6E\N
MU7=N(P1MD(^4GJ<\XKUO5;-=4TB\TTRA%NX'A+C!V[E*YQWZUX=X;673/'ES
M9VS?Z/;WE[8ES*YD^SW$\*(R.#E6!B(![!>*+6.Z$W6CRRLVD[>A[S/>6MO-
M'#-<)'++DHK, 6QC.,_4?G7,:'K&FGQUXCT^'4+>=9$AOB$<'8P7R9 WH1Y2
M'_@5>6Z/:CQUI'AW3=4UBZ\TV\=LVII<%KF=EAM[IT=L  []PX.<#KD<U?'%
MK>>'-8DTW2]0DNT:VN/M:2'?<RVTL%T[*K'^%6"L<_,2G49.7<B.'C9)M\S5
M_P ;'='3;O6='\#:C:QLY'B ZK.57.(9#</D^V6CY^E>JM(NW[W<?SK"\+K9
MV_AS3;.QNHKBVM;6*V22)PZG8-G!'TK>=TV_>'4=_>@Y))Q;3'^8G]ZF+(FW
M[W<_SI^]/[P_.FHZ;?OCJ>_O0(/,3S/O=J'D38?FHWIYGWQT]:'=-A^<?G0!
M&9%\R;YOX!_6I?,3'WJB+IYDWSC[@[_6I@Z8^^/SH 8LB9;YN_\ 2D:1=Z?-
MZ_RI5=,O\PZ^OM0SIO3YQW[T *TB?+\W>G>8G]ZFLZ?+\XZ^M.WI_>'YT 10
M2)]GC^;^$4Y9$Q][N?YTV!T^SQ_,/N^M/5TQ]X=3W]Z #S$\P?-VH>1-A^:C
M>GFCYQT]:)'38?G'YT .\Q/[U0+(GG_>[-_.I]Z?WA^=0*Z?:/OC[K=_>@#!
MAE6'XE7L?07.EPR?4QRR _\ HP55NM<UBZU74-/T#2;>Z6S(ADO+JY\N))2@
M<KM52S !ESCN<<8)K,\77%]'XX\-V^ES2076J0W%D;F-5;[.BM%*[_,"N=B.
M!D$985TND:;#H^EFQ2Z>=BTDTD\Q7S)I'8LSM@ 9))Z  < =* $T/5/[6TYI
MY83:W,,SV]Q 6W>7*AVL W\0[@]P1P.E;:R)N;YN_P#2N=T&2.#Q)XGL<@#[
M7%=+SVDA0?\ H4;U?U;6M,T.PDU#5KV.UM1+'%YC\C<[*BCCGEF H TVD3>G
MS=_Z5YQXPDM?$DOV?2[B*\^S:=J,@,#!P)T*1A>/X@^X$=016_XBU&YFN8O#
M.DW!34+P9EFC;FQM^C3$]F/*H#U8YY"MAND^$=,\/:_<ZIIK&&&XMX+5;-,>
M7"4)RZ]\L-@;UV ]2: +'AWQ-;^(H;B:WM+NS:!U4QW<?ENRM&KJ^WJ 0W&[
M!X.0*Z..1/+7YNU<?<:GI^A^/;N74+R"RMM0TZ.42S2A%+PNP?D]]LB?@*E\
M.^)GUK4KZUFL&L84CCN+%Y6(>ZMV)7S"A *?,AP#SM9"<$X !U7F)YA^;L/Z
MTK2)@?-W%)O3S#\PZ#O]:5W3 ^<=1WH =YB?WJB@D3RE^;U_G4N]/[P_.HH'
M3R5^8=^_O0 _S$\S[W:AY$V'YJ-Z>9]\=/6B1TV'YQ^= #O,3^]35D3!^;N:
M=O3^\/SIJ.F#\XZGO0 GF)YJ_-V/]*CCD3[,/F[&I"Z>8OS#H>_TID;K]F'S
MCH>] $WF)_>IBR)\WS?Q4_>G]X?G3%=/F^<?>]:  R)O7YO6AI$ROS=_Z4I=
M/,7YQW[TC.F4^8=?7VH ;+(FQ?F_B7^8KCOB!9KKNA6WA-3SK$AC<=_+C0RD
M_P#?2(O_  *NIU*]AL-)NK^5AY=M&T[<]E&X_P JXSPG?:IX@UQ=3US33I]S
MIMBELT0!,3338DD:)C]Y-BPX/;+*>0: +7]I+K<G@>7K)<_\3)\?PJMLP/\
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M8WRCIZ4!5V#Y1T]* !-NQ>G2HYMOES=/N?XT]%78ORCIZ4R9%\N;Y1]ST^M
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M^:_W@3A ?+(! Y.<\FO:U5/F^4=?2@TJ0Y+:[I,#&F]?E'?M7)>-E3[=X/\
ME'_(>B[?],)JZ1I+=+J&W>2)99 Q2,D!G QG [XR,_6O.?B)XDT6UU[0M)N+
MEEN[;4(KJ15A=_E>&X08V@Y(.,@<@,">#F@B*NTC:D_M*;Q'KC:3Y7GJMI;_
M &B3!6-EWR,K G)&R12,#/S]3CCI=&%\^CV[:M$B7I7]ZJ@8!]J\CT'5DU7X
M82ZE 9%\S7-/3>QYD5+BTC# ]2&51]<UW=]XNN+6:1;?0Y[ORGF5A'G/[LJ
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MMUKP_>R:/JD?]K7L+Q7<UUL\A([!R!))A<C<C[E"YR0 2>":]'D0;#U_[Z-
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M<_H*>'ETR6/PS]G&GHVW%J?DWYRW\Q70!/WC?,W0=Z $=5^7K]X=S4FU??\
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M"2Y\/S0O9 ^7FW3:A<'G P/4<UNA3YC?.>@]*Q-(OM,U&Q:XT=5CM#MP$C"
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MY_TH BVG[2WS'[@]/4UGZUIMGJFBW%GJ$(GMV3+1OT;!W#/X@5H[6^T-\W\
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M6M[9*TRFWA&6A?>"JEL\[1E<$#&>_9#XXTG[-#<K'=O#(S*62,-Y>'"9<#D
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M&)/X)-W+XP?X<C\:LZ+9ZI:Z%Y%]>_:+P!P)NN[DX.. .W P.*W,/_>'Y5%
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MP.I%6V5L#Y^X[54LCML[?<P&8T R.O%6V#8'S#J.U,F6X[#?W_TIJ*VP?/\
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MTZ:66*&.2-U,388;3P,G-'+?J;1GRNZBCD=/CU:QU"WNA97A0-F18HB"X P
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MN;8K+NNXWA8JR8^Z&"Y.>.<=ZQ])G\5V-W)>ZC:?:[R5$5BD#*I 0Y' &,L
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&HIB>I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>lxrp_ex991img10.jpg
<TEXT>
begin 644 lxrp_ex991img10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #[ <X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z[M+2U:R@
M9K>)F,:DDH"2<5/]BL_^?6'_ +]BBS_Y!\'_ %R7^56: *WV*S_Y]8?^_8H^
MQ6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6?_/K#_W[%6:* *WV*S_Y]8?^
M_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6?_/K#_W[%6:* *WV*S_Y
M]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6?_/K#_W[%6:* *WV
M*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6?_/K#_W[%6:*
M *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6?_/K#_W[
M%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6?_/K
M#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8H^Q6
M?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8?^_8
MH^Q6?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_ )]8
M?^_8H^Q6?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?8K/_
M )]8?^_8H^Q6?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59HH K?
M8K/_ )]8?^_8H^Q6?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?L59H
MH K?8K/_ )]8?^_8H^Q6?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP_P#?
ML59HH K?8K/_ )]8?^_8H^Q6?_/K#_W[%6:* *WV*S_Y]8?^_8H^Q6?_ #ZP
M_P#?L59HH K?8K/_ )]8?^_8K-UJWMX;)&2WC!,@'RJ!Q@UMUDZ[_P >,?\
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M?[)'_>F_[_O_ (T7'_'Q:?\ 74_^@-5B@"O]DC_O3?\ ?]_\:/LD?]Z;_O\
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MLMJT $07DY$DB$\>@- %2_L=>=M.O+5+&YN]/D('GSM$MRC1;68E8SY;;N0
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M?]<E_E7(>,/"LFO7<-U'IFE:@4MIK;R]2R!"7*D2H0C?,-IXXSG[PQ77V?\
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MTB/[/$>QE?ER/H/E-=GU6N2E[\Y5/DO1&]3W(QA\WZO_ (!%]DC_ +TW_?\
M?_&J]M:QM"Q+2_ZR0<3./XS[UH56M/\ 4O\ ]=9/_0S768"?98L?>F_[_/\
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MKNB3GTDM74#\C56W7XK1@K')X7FC$C9+BX5F.XYZ<#G.*R]FNC17M/[K._\
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MY_9OR3_XFIZ* *_V>7_G\F_)/_B:7R)?^?R;\D_^)J>B@"#R)?\ G]F_)/\
MXFCR)?\ G\F_)/\ XFIZ* ,^:&036W^F2G,AY(3CY&_V:L^1+_S^3?DG_P 3
M27'_ !\6G_74_P#H#58H @\B7_G\F_)/_B:/(E_Y_)OR3_XFIZ* (/(E_P"?
MV;\D_P#B:/(E_P"?R;\D_P#B:GHH K_9Y?\ G\F_)/\ XFE\B7_G\F_)/_B:
MGHH @\B7_G]F_)/_ (FJUK#(86Q>2K^\DX 3^^?]FM"J]I_J6_ZZR?\ H9H
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M?_$U/10!7^SR_P#/Y-^2?_$U$L;1W\6Z9Y?W3_>"\<KZ 5=JNW_(0A_ZY/\
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M-3T4 0>1+_S^S?DG_P 31Y$O_/[-^2?_ !-3T4 0>1+_ ,_LWY)_\31Y$O\
MS^S?DG_Q-3T4 0>1+_S^S?DG_P 35>:&036W^F2G,AY(3CY&_P!FK]5[C_CX
MM/\ KJ?_ $!J %\B7_G]F_)/_B:/(E_Y_9OR3_XFIZ* (/(E_P"?V;\D_P#B
M:/(E_P"?V;\D_P#B:GHH @\B7_G]F_)/_B:/(E_Y_9OR3_XFIZ* (/(E_P"?
MV;\D_P#B:/(E_P"?V;\D_P#B:GHH S[6&0PMB\E7]Y)P G]\_P"S5GR)?^?V
M;\D_^)I+3_4M_P!=9/\ T,U8H @\B7_G]F_)/_B:/(E_Y_9OR3_XFIZ* (/(
ME_Y_9OR3_P")H\B7_G]F_)/_ (FIZ* (/(E_Y_9OR3_XFCR)?^?V;\D_^)J>
MB@"A-#()K;_3)3F0\D)Q\C?[-6/(E_Y_9OR3_P")I+C_ (^+3_KJ?_0&JQ0!
M!Y$O_/[-^2?_ !-'D2_\_LWY)_\ $U/10!!Y$O\ S^S?DG_Q-'D2_P#/[-^2
M?_$U/10!!Y$O_/[-^2?_ !-'D2_\_LWY)_\ $U/10!!Y$O\ S^S?DG_Q-5K6
M&0PMB\E7]Y)P G]\_P"S6A5>T_U+?]=9/_0S0 OD2_\ /[-^2?\ Q-'D2_\
M/[-^2?\ Q-3T4 0>1+_S^S?DG_Q-'D2_\_LWY)_\34]% $'D2_\ /[-^2?\
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MF_)/_B:/(E_Y_9OR3_XFIZ* ,^UAD,+8O)5_>2< )_?/^S5GR)?^?V;\D_\
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M"#R)?^?V;\D_^)H\B7_G]F_)/_B:GHH @\B7_G]F_)/_ (FCR)?^?V;\D_\
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M-'D2_P#/[-^2?_$U/10!!Y$O_/[-^2?_ !-'D2_\_LWY)_\ $U/10!!Y$O\
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M%_\ $4?8KG_H+7?_ 'S%_P#$5=HH I?8KG_H+7?_ 'S%_P#$5$EC-'E5U2Z
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M.+_A0!V%%<?_ &UJ7_/S_P".+_A1_;6I?\_/_CB_X4 =A17'_P!M:E_S\_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>lxrp_ex991img11.jpg
<TEXT>
begin 644 lxrp_ex991img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $6 <4# 2(  A$! Q$!_\0
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M_BJAN]0L=/B$E]>06L9;:'FD" GTR3UJX&# $'(/<46>X$7GR_\ /G-^:?\
MQ5'GR_\ /G-^:?\ Q53T4 0>?+_SYS?FG_Q5'GR_\^<WYI_\54]% $'GR_\
M/G-^:?\ Q51"Z8RF/[)-N #$93H<X_B]C5RJZ_\ (0F_ZY)_-Z %\^7_ )\Y
MOS3_ .*H\^7_ )\YOS3_ .*J>B@"#SY?^?.;\T_^*H\^7_GSF_-/_BJGHH @
M\^7_ )\YOS3_ .*H\^7_ )\YOS3_ .*J>B@"#SY?^?.;\T_^*J(7#>8B26\L
M>\[06*D9P3V)]*N57N/^/BT_ZZG_ - :@"Q1110!BZYTM_\ @7]**-<Z6_\
MP+^E% &C9_\ (/@_ZY+_ "JS5:S_ .0?!_UR7^5<HUUJEOXY9=2FU2/39YA#
M9A5M3:.3"#M8@&<-N$G)PO &><$ [2BN \1>+[6P\2VFDMK]IIY@FA-U'--&
MKS"1L! &YVA<L6&"/EYZUW] %&S_ ./S4O\ KX'_ **CJ]67;W%O#>ZBLL\<
M;>>#AF /^JCJW]ML_P#GZA_[^"@"S15;[;9_\_4/_?P4?;;/_GZA_P"_@H L
MT56^VV?_ #]0_P#?P4?;;/\ Y^H?^_@H LT56^VV?_/U#_W\%'VVS_Y^H?\
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MCJU &A15;[;9_P#/U#_W\%'VVS_Y^H?^_@H LT56^VV?_/U#_P!_!1]ML_\
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M%%% %=O^0A#_ -<G_FE6*KM_R$(?^N3_ ,TJQ0 4444 %%%% !1110!7N_\
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M_O3?]_W_ ,:/LD?]Z;_O^_\ C0 -_P A"'_KD_\ -*L50:UC^W1+NEP8W/\
MKGSU7WJ?[)'_ 'IO^_[_ .- %BBJ_P!DC_O3?]_W_P :/LD?]Z;_ +_O_C0!
M8HJO]DC_ +TW_?\ ?_&C[)'_ 'IO^_[_ .- %BBJ_P!DC_O3?]_W_P :/LD?
M]Z;_ +_O_C0 7?\ J5_ZZQ_^ABK%9]U:QK"I#2_ZR,<S.?XQ[U8^R1_WIO\
MO^_^- %BBJ_V2/\ O3?]_P!_\:/LD?\ >F_[_O\ XT 6**K_ &2/^]-_W_?_
M !H^R1_WIO\ O^_^- $U9.N:E'HN@W^J3 %+2!Y<'^(@9 _$\5?^RQ_WIO\
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M_P!_W_QJ"2!([BU96DSYA'S2,P^XWJ: +]%%% &+KG2W_P"!?THHUSI;_P#
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M -#-6*KVG^I;_KK)_P"AF@"Q1110 4444 %%%% !5=?^0A-_UR3^;U8JNO\
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MY80+,JQWB0!R20N"-FX$\<=:[VBB@#FM-T>PM=4U.XL;>*SEDG D:WAC4O\
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M(E_Y_9OR3_XFCR)?^?V;\D_^)J>B@"#R)?\ G]F_)/\ XFCR)?\ G\F_)/\
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M-2\#ZD=&N7.Z2R<%[.8^Z?P?5>G8"F?\+(70U>V\;:3<:->HI*M&AF@N<?\
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MD17O_(.N/^N3?RJS5:\_Y!\__7)OY59KL, HHHH **** "BBB@ JO:?ZEO\
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MY/\ S2K% !1110 4444 %%%% %>[_P!2O_76/_T,58JO=_ZE?^NL?_H8JQ0
M4444 %%%% !1110!6O/^0?/_ -<F_E5FJUY_R#Y_^N3?RJS0 4444 %%%% !
M1110 57M/]2W_763_P!#-6*KVG^I;_KK)_Z&: +%%%% !1110 4444 %5U_Y
M"$W_ %R3^;U8JNO_ "$)O^N2?S>@"Q1110 4444 %%%% !5>X_X^+3_KJ?\
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M0I4'<>!FF3>+O#L-K%?27<WE2^8<"TF9T$9VR%T";HPIX8L !QF@#<\O5?\
MG\M/_ 9O_CE'EZK_ ,_EI_X#-_\ '*M*RLH92"IY!'0T^@"EY>J_\_EI_P"
MS?\ QRCR]5_Y_+3_ ,!F_P#CE7:* *7EZK_S^6G_ (#-_P#'*/+U7_G\M/\
MP&;_ ..5=HH I>7JO_/Y:?\ @,W_ ,<J&.WU2-"JWEJ069N;9NY)_P">GO39
MM5L8=5M],DN-MW.K21Q[&(VKU).,#OC)&<'&<&LN+QAX?GM;BXCO)-D"QMDV
MLJF178K&T8*YE#$84H&!/3- &YY>J_\ /Y:?^ S?_'*/+U7_ )_+3_P&;_XY
M4.GZA::Q8+>6,C/"69/GC:-E96*LK*P#*00000#6G0!2\O5?^?RT_P# 9O\
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M:3@]:WJ ,77.EO\ \"_I11KG2W_X%_2B@#1L_P#D'P?]<E_E5FJUG_R#X/\
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MSWK0M_$VEZ9::E>:QXFCFMX]3:S\R2V,*VK'&(2<<@?WSQSUXH [&HVW!#M
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M:R??A@2-OJ% J]110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR/\ &C^VK7_GG+_WR/\ &BB@ _MJU_YYR_\ ?(_QH_MJU_YYR_\ ?(_QHHH
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?O_?(_P :** ,77+NTOA;EED&W=_".^/?VHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>lxrp_ex991img12.jpg
<TEXT>
begin 644 lxrp_ex991img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  7 $<# 2(  A$! Q$!_\0
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1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140482603787408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexaria Bioscience Corp.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001348362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 24,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-52138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2000871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">100 &#8211; 740 McCurdy Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Kelowna<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">V1X 2P7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">765-6424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LEXX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>lxrp_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrp-20240124.xsd" xlink:type="simple"/>
    <context id="From2024-01-24to2024-01-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001348362</identifier>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-01-24to2024-01-24">0001348362</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-01-24to2024-01-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2024-01-24to2024-01-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-24to2024-01-24">2024-01-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2024-01-24to2024-01-24">Lexaria Bioscience Corp.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-24to2024-01-24">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2024-01-24to2024-01-24">000-52138</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-24to2024-01-24">20-2000871</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-24to2024-01-24">100 &#x2013; 740 McCurdy Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-24to2024-01-24">Kelowna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-24to2024-01-24">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2024-01-24to2024-01-24">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-24to2024-01-24">V1X 2P7</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-24to2024-01-24">250</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-24to2024-01-24">765-6424</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2024-01-24to2024-01-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2024-01-24to2024-01-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2024-01-24to2024-01-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2024-01-24to2024-01-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2024-01-24to2024-01-24">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-24to2024-01-24">LEXX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-24to2024-01-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-24to2024-01-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
MQ1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\
M3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4
MKS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2
MG0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 10
M2P,$%     @ @W$X6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#
M, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M
M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD
M%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3
MY?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^
M-8+)#^Q^ %!+ P04    " "#<3A8JL0B%C,!   B @  #P   'AL+W=O<FMB
M;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;
MJAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q
M8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST
M=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?
M5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#B
MG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.
M>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]0
M2P,$%     @ @W$X6"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!
MD#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&
MO-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S"
M:+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X
M=/X!4$L#!!0    ( (-Q.%AED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP
M97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*
MH!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJU
MDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7
MQ<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!Z
MVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$
M?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q
M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ @W$X6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "#<3A86QY!0>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "#<3A8F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (-Q.%B)
MYZRV6 0   L1   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "#<3A8GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (-Q.%B7BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M (-Q.%BJQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "#<3A8)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "#
M<3A899!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="lxrp_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lxrp.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>lxrp-20240124.xsd</File>
    <File>lxrp-20240124_cal.xml</File>
    <File>lxrp-20240124_def.xml</File>
    <File>lxrp-20240124_lab.xml</File>
    <File>lxrp-20240124_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="lxrp_8k.htm">lxrp_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lxrp_8k.htm": {
   "nsprefix": "lxrp",
   "nsuri": "http://lxrp.com/20240124",
   "dts": {
    "schema": {
     "local": [
      "lxrp-20240124.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lxrp-20240124_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrp-20240124_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lxrp-20240124_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrp-20240124_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrp_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://lxrp.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-24to2024-01-24",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrp_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-24to2024-01-24",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrp_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001640334-24-000137-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-24-000137-xbrl.zip
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M37ZN9I@'_4O?Z$'/ZC<\RX?VW:"H*R_\$X)V_W.LVY^%J;ZK;U!+ P04
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MH]^].^FP)[<KI7)[YTV<W<VCJ_VX>0%02P,$%     @ @W$X6 4_; R3 @
M1 @  !4   !L>')P+3(P,C0P,3(T7V1E9BYX;6R]5=UKVS 0?Q_L?[AY#]M@
MLN*DA34T+6F[AT(Z1KJ-OA5%OL1BLA0DY:/__71V["4TA6:0Y2'8OM_7G67I
M_')=:EBB\\J:09*EG0302)LK,QLD"\^$ETHEX(,PN=#6X"!Y0I]<7KQ]<_Z.
ML8>K\0ANK%R4: )<.Q0!<UBI4 "5[H0/Z!C;H'_5/GWHIKVT\Z5]?B5\9%E3
M<6(Q:RLW40_L%"0I5]1.QKLGO-OIGK2@>SL-*^$0A).%"BC#P@D-.7HU,Q"#
M0]U0'X8?)-P4PI5B[K 4AIJ"X3*DK=:UG3\Y-2L"?)2?@&S@EGW[^@.N%EX9
M]![NK5Y0%/\9;HU,8:@UC(GA88P>W1+SC9Q6YG>?_B:Q/XB#-KZ_]FJ0%"',
M^YRO5JMTU4NMF\5^8E\/=Z-[6<1<3!D:N,2D89'*/EYV=G;&JVH#?89<3YQN
M/'J\B=,JQVH>6L(V^)37Q0CUJN^K9",KJ_?P"@=X$4%WK($Q>L2R+NMEZ=KG
M21P<0#TZ9S6.<0I %S_'MZVI7KMY*FW)J<"O;5R_,63%*1Q.!PD!&+V\3M8]
M(=GW.Z#P-(_KV*MRKN,@^)9E7$&-ZS[HML<+[353H[Y.*^LB2CBYF"#+5?Q,
MZ M(8&.TW56KHDS@$<HW&+Y7X-BI6RN6VU*H R,_9Q\];^7#2BPG]*(/"KM+
M/792H?5A^2K"L5,9&X:'!FLX_W$MXE0L=/CGQ=C0MQ/'A\HHVM5&\78G-:X#
MFASS)C?)O687"BH0L%/_,F!_ST@&%1*^BQG& V1JXV%$WO7&UV325NX$T;3O
M6O=\?KYIW*-,9W;)<U1T.O;H@K; 7CU!5(^5[W#B@Q,R-$I:3%!7^H\1LVEB
M,QV^9SQTKO&=@^WB#U!+ P04    " "#<3A86F?_!"D&  "#.0  %0   &QX
M<G M,C R-# Q,C1?;&%B+GAM;,U;76_;-A1]'[#_<.<]; ,F*TZ*83&2%*Z;
M%L:<#\3N5FP8"EFB;6(2:9!T;/_[D?J*)9%2$K247F)9/(<\E_?H2B:5B[?[
M*(1'Q#BFY+(WZ)_T !&?!IBL+GM;[GC<Q[@'7'@D\$)*T&7O@'CO[=7WWUW\
MX#B?WSU,X3WUMQ$B L8,>0(%L,-B#:KIQN,",<=)T7\FXPSAM'_6/_D]/__.
MXY)%2<R1C8.\Y;WL#^@2?-5S3#T9N*=OW-.3TS<Y:$:78N<Q!![SUU@@7VR9
M%T* .%X1D,(A"6@(HY]\>+_V6.1M&(H\HH*"T:/HYWV-Z>; \&HMX&?_%U##
MP,2YO9[#NRW'!'$.,QINE13^*TR(WX=1&,*#8G!X0!RQ1Q2DW868_#=4?Q8R
M/I 33?APS_%E;RW$9NBZN]VNOSOK4[:2\<BX/M],9_Y:ZG(P41/NHU[&4KWH
M>(/S\W,W;LV@%>1^P<)LC#,WDR/A' ]Y/-R4^O'D/H,&1H3ZYF0P1YUR!J?.
MV:"_YT%/S@9 ,A^,AN@!+2$6/12'C704Q]$F5)+B<VN&EGHI(6.NXKL$K931
MU##G:IC!;VJ8']/34V^!PAXHY*>'B3&J\T)?*<E]IM27=7Z/&*;!-<E&^4J!
MEKM]KOBO.OQ,>$R\:LJK?,L!S*GPPE=)/V9:%GV+7C?;3SS;LRRK/GK=+!\Q
MOX%H417\XJG5S6FH3DWE44$@V@M$ A1D$E4'-14W[C\N[''/>=_4+_0:JMI-
M635N+GN->^3([Z_HHQL@K&Z;9^K 40=QR/++ES&5#P"C!1?,\T764QS$94_3
M[A8%*=R(9:KD+;@AL!3A^E3>X#;""8]+XI+12#MH&C/5-'X)%SD_F10YA%9F
M <00IUOFHQ?EXUBK:892/5$H$>HI"A'GTZQW%6/@GPSU[X7[U,LW3_$U$5@<
M'M *J]&)N/4BI(E##[.3\#J)6=YUF ZDOT96V04)%)ZPH, M>&$L']CE4_)$
MEJ3]'^A@C*J"L^D&@\BB'4J@SOA!K\M@B!0,,1HDW*HELE]P<]FC)IYBLQT#
MZ"1E>3]NZT"Z-7+*6<Y_(BN,U=2.Y+"!&OI#Z*TTXDOM=I*K%95EM]#8@?3J
M])3SFV- @5HHY]<18BM,5A\9W8GUF$8;CYB+N@%ML[37"BX6>"VT \9H5F<H
M]AD%$@ZDI%9*?KZ&H);::HI;"6?W)J 56;X;%$ =L$>=+N/](0&#1(."MU!)
M/N 0W6ZC!6)&RQ]#;-:,JK1BH7AJ[T#Z#9(,)4'A( &VD/,)\2G;4!8O \^$
M--Z8;N4#Z6%, _/OQ :636<\*X"B66HIG?'/<U0:+%6@0LR%E R*W8+/YMY^
M$L@RAY<XV7)H*#1&O$UO-8@NNLH [HR?ZO49G"1)4&2U5ZI&02!GA:<?4TS0
MP!BL%FO3.C5BB[;1 #MC&;,V@UU29/ZI*#!HSRMC>7C'YG1'FF(\1K;@DZI0
MK4N>8%WS2$59@T,4'NX8*$9[_KBG7'CAWWA3^[2C![?@$JU<K5$*R*YY12>N
MP2X)!23'_@.,LNJ((<_@D6*SI2TRC:1\A^RHK0.9U\BI[(_%F988^[E5+\"$
M]VM*S#]\JQ [.39)R_)<;N] K@V2ROF.81#CVGB:G"%_RZ3E!J>+.1:A[IJN
M0NSDW"0MRWFYO0,Y-T@JYSR#@<1!#+2:\SGSU'N LT.TH+HH2NUVLJT5E:6Z
MT-B!/.OTE).<8B !M7)17^_]M92$#*\YZ&%V+VZ=Q/(%?HSI0/)K9!DO] QK
M_S6'O^3X I$QC:(M29<MN"8J \Z.&VI%9G;0@CK@ASI=94.D6"B"[18'&F(?
M"UF:;CR!&/:T'M> +!4&H[R\+%00'3"!452E).1 R)!6TW_/D#(?DDF(7]90
M+V.RN^52^[A?![9CAV:YF2W,R [8HU%<V2:2 ,<,2"@0<]HTS(3S+6(OLHV&
MTHIYC-(-%JK@NV<DD\1&.R7$]EQ56 .+-^7NV#VCCYCXC6N/%7@+JX\&R=KU
MQQ*V RYZAKR&-<AD'_6.049K<5\CV<QM7)3/8&WL:!0EZK<S$DS7W%&4U;21
MD8 K7C@^,95'ZM\"TU,X^5>YJ_\!4$L#!!0    ( (-Q.%AO%A(8E00  &4D
M   5    ;'AR<"TR,#(T,#$R-%]P<F4N>&ULQ9I=C^(V%(;O*_4_N/2BK=00
M M-V!\WLBF'8%>I\(*#MJC<KDQS JF,CVPSP[WL<",M'$MR+XKG@(WEMG_?Q
MB2?'X>[#.N7D#91F4MS7HGJC1D#$,F%B=E];ZH#JF+$:T8:*A'(IX+ZV 5W[
M\/[;;^Z^"X+/#\,G\BCC90K"D*X":B A*V;FQ)YZIMJ "H*=^L_M.&W2K+?J
MC7?[XP]48RLILC9X,MJ?><3^B)R2V/:<-6U$8?,F;#::-WO12$[-BBH@5,5S
M9B V2T4Y24"SF2 8.-D::I/.#S%YG%.5TH6"E IKBG3>3'W?5U<N-HK-YH;\
M&/]$[#"D'[STQN1AJ9D K<E(\J4-1?],^B*NDP[G9&A;:#($#>H-DEUWG(E_
MVO9E@OX(@A:ZO=;LOC8W9M$.P]5J55^UZE+-T _Z^OS\-(KG&%? A 4>0RUO
M97LI:A?=WMZ&V=E<>J9<3Q3/QVB%>3@HUZRML^&>9)S!=6A&2A7V6Y#+ GLH
MB)I!*ZJO=5)#&H1L>2C)80A38M__&/;W8_*U6M1CF8;V1-B5F),88]9DKF!Z
M7[."P$Y((VK>V%Z_/Q*9S0)S4[-TP=%<># B3K7&[,PL/N&!HP:P-B 22/)N
M[.@N,1EFK+"Q_8M(\/4J"$BF) ,Z TR1J<1TLV-O*>11<1D?!<+M),@3SS8.
MC8%DJ#7$]9E\"Q-@-O];]H,%TLI@X)<OV;B=B3:*QB;OB=,)\*S_+Z@YD83_
M>TP]@:@V0Y@Q.Z8P+S2%XM"*E<<1'LYE1\5$J@043D/>(ZX 1S-XGJ<[1;C
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MS<VRA@3?@+@NN,^@K<?D6H4F:[_L5([FN9\R)4\&2YW5_F;Y\"J">CJ$5=^
M'+MTU$X*2ZXQO76%6BY99=C^T:&S@DT]%YF2W[<=@XR[(4(2 :A<DM\ E"N/
M&]B^6> &$8]G_=[[K+YMPMELDHM-,1QRI3;.-'0])%;3]\M<Q78=0\:BOY4*
MMSNWI#4,?3%F<K/LGW47,3>N1/%O3/923%;=7P@4/:&U&&X_W7DZ5IQYGF1*
M)?]\A@3<63U..+#S']\=E1VG3@ZK)7+I-B/IC4E'4&\^<NPM+Y[-K*0)?U[+
MKG@,5E_')^8#_0( 7'5*$RJNY0T@2FZ.XE>=]T-S?LI5-QG#X)=#X.1@.@7
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MK""X4LY@:76++Z$>F+KTKINBHEWL5Z0:G 2T:O"$8H$@EZAR+',W6-S5Z8_
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M@5;><GDXN\7A;O$^+!IR=V]P%Q\)V*8@2&2/V%_$1:^>*]"JP>K2]0$_M2E
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MX%B:*=-82Y6#' 0:6WE=:,B7.IJR!-?67IF0O];WV$9%Z:P+*3F<,>W;MB$
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M,XC,: .HOP0P4FU7AW)]C@L/Z:("<@:1R) 3.D;IH5B- Z9(*106OSH< DX
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MEJ%U0;R#M*D%JQ5:.T2? ]@TE;3LJPUC PYYG%9@8L"UD-"YED/'="^Y==+
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M     &QX<G M,C R-# Q,C0N>'-D4$L! A0#%     @ @W$X6'DB.$G; 0
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7;5!+!08     !P ' , !  !V7P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
